Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

▴ Lilly's oral GLP-1
In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (8.9 kg ;9.2%) compared to 11.0 lbs (5 kg; 5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss.

New Delhi, February 26, 2025 – Eli Lilly and Company today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight.1,2 The results were published today in The Lancet.

 

"ACHIEVE-3 gives us the first head-to-head comparison between two oral GLP-1 receptor agonist therapies in adults with type 2 diabetes, and the differences were clinically meaningful," said Dr. Julio Rosenstock, clinical professor of medicine at the University of Texas Southwestern Medical Center and lead investigator. "Orforglipron 12 mg and 36 mg doses outperformed oral semaglutide 7 mg and 14 mg diabetes-related doses on every key endpoint we measured, including A1C and weight loss, with improvements appearing as early as four weeks and sustained throughout the study.”

 

 

ACHIEVE-3 Full Results

 

Oral Semaglutide 7 mg

Oral Semaglutide 14 mg

Orforglipron 12 mg  

Orforglipron 36 mg

Primary Endpoint

Change in A1C
from baseline of
8.3% at week 52

Efficacy estimand2

-1.1%

-1.4%

-1.9%i,ii

-2.2%i,ii

Treatment‑regimen estimand3

-1.2%

-1.5%

-1.7%i,iii

-1.9%i,ii

Secondary Endpoints

Change in
weight from
baseline of 97.0
kg (213.9 lbs) at
week 52v

Efficacy estimand

-3.7%

 

(-3.6 kg; -7.9 lbs)

-5.3%

 

(-5.0 kg; -11.0
lbs)

-6.7%i,iii

 

(-6.6 kg; -14.6
lbs)

-9.2%i,ii

 

(-8.9 kg; -19.7
lbs)

Treatment‑regimen estimand

-3.9%

 

(-3.8 kg; -8.4 lbs)

-5.3%

 

(-5.2 kg; -11.5 lbs)

-6.1%i

 

(-6.2 kg; -13.7 lbs)

-8.2%i,ii

 

(-8.1 kg; -17.8 lbs)

Percentage of

participants

achieving A1C
<7% at week
52

Efficacy estimand

54.6%

66.1%

80.0% i,ii

85.4% i,ii

Treatment‑regimen estimand

53.9%

63.8%

72.2% i,iii

75.8% i,ii

Percentage of

participants

achieving A1C
≤6.5% at week
52

Efficacy estimand

40.9%

50.9%

71.8%i,ii

76.8%i,ii

Treatment‑regimen estimand

38.4%

48.3%

62.7%i,ii

67.7%i,ii

Percentage of

participants

achieving A1C
<5.7% at week
52iv

Efficacy estimand

7.8%

12.5%

25.4%i,ii

37.1%i,ii

Treatment-regimen estimand

7.4%

11.7%

21.4%i,ii

31.4%i,ii

ip<0.001 vs. oral semaglutide 7 mg

iip<0.001 vs. oral semaglutide 14 mg

iiip<0.01 vs. oral semaglutide 14 mg

ivBody weight for orforglipron 12 mg vs. oral semaglutide 14 mg, and percentage of participants achieving A1C <5.7% were not controlled for family-wise type 1 error.1

 

Orforglipron also showed clinically meaningful improvements from baseline across key cardiovascular risk factors, including non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure and triglycerides.4

 

"The results of ACHIEVE-3 highlight the potential advantages of orforglipron over oral semaglutide for type 2 diabetes: greater A1C reduction, more weight loss, and the ability to take it without food or water timing restrictions — that's a combination that could matter significantly to people managing their disease day-in and day-out,” said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health. " With global submissions underway and FDA action on obesity expected next quarter, we're focused on making this option available as quickly as possible."

 

The overall safety and tolerability profile of orforglipron in ACHIEVE-3 was consistent with previous trials. For orforglipron and oral semaglutide, the most common adverse events were nausea, diarrhea, vomiting, dyspepsia and decreased appetite. Treatment discontinuation rates due to adverse events were 8.7% (12 mg) and 9.7% (36 mg) for orforglipron vs. 4.5% (7 mg) and 4.9% (14 mg) for oral semaglutide.

 

Lilly has submitted orforglipron to regulators in over 40 countries, with submission for type 2 diabetes in the U.S. planned later this year.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026